Moderna (MRNA) closed at $34.01 in the latest trading session, marking a -1.9% move from the prior day. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the ...

Moderna stock rises on flu vaccine data and FDA approvals, while healthcare stocks remain under pressure amid political ...

These issues could continue to weigh on Moderna's stock performance. But even considering this, and the fact that its pipeline hasn't yet pushed it onto investors' buy lists, I still wouldn't dump ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA).Once a stock market star generating billions of dollars in coronavirus vaccine revenue ...

A few years ago, Moderna (MRNA-2.92%) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from drawing board to commercialization in less than a year and ...

Moderna’s stock remains far below its 52-week high of $170.47 and is down more than 65% over the past year. ... less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

The S&P 500 fell 0.1% on Tuesday, July 8, 2025, after President Trump extended the deadline for "reciprocal" tariffs and ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about MRNA stock here.

Moderna’s stock (NASDAQ: MRNA) has fallen over 80% in the last year, primarily due to issues with its vaccine sales. Last year, the company revealed reduced sales forecasts in Europe after the ...